Infect Chemother.  2016 Dec;48(4):257-266. 10.3947/ic.2016.48.4.257.

Indirect Effects of Pneumococcal Conjugate Vaccines in National Immunization Programs for Children on Adult Pneumococcal Disease

• Kim YK
• LaFon D
• Nahm MH

• KMID: 2441319
• DOI: http://doi.org/10.3947/ic.2016.48.4.257

Abstract

The pneumococcal conjugate vaccine (PCV) was developed to overcome the limitations of the pneumococcal polysaccharide vaccine, which produces poor immunogenicity in infants younger than 2 years. As many countries have included PCVs in national immunization programs for children, the incidence of invasive pneumococcal disease caused by vaccine type Streptococcus pneumoniae has declined markedly, not only among the vaccinated pediatric population, but also among unvaccinated adults. In this review, we present a concise overview of the indirect effects of mass pediatric PCV immunization on unvaccinated adults.

Keyword

Pneumococcal vaccines; Pneumococcal infections; Mass vaccination; Immunity; Herd

MeSH Terms

Adult*
Child*
Humans
Immunization Programs*
Immunization*
Incidence
Infant
Mass Vaccination
Pneumococcal Infections
Pneumococcal Vaccines
Streptococcus pneumoniae
Vaccines, Conjugate*
Pneumococcal Vaccines
Vaccines, Conjugate

Figure

• 

  Figure 1 Countries with Pneumococcal Conjugate vaccine (PCV) in the national immunization program and planned introductions in 2016, adapted to include dates of introduction for PCV for selected countries, organized by WHO region World Health Organization. Immunization, Vaccines, and Biologicals-Data, statistics and graphics. Updated 01 December 2016. Available at http://www.who.int/immunization/monitoring_surveillance/data/en Accessed 7 December 2016. *Includes partial introduction

• 

  Figure 2 Trends in the incidence of invasive pneumococcal diseases according to serotypes among unvaccinated adults PCV, pnemococcal conjugate vaccine. *Incidence is not real number

Reference

1. Anonymous . Pneumococcal conjugate vaccine for childhood immunization--WHO position paper. Wkly Epidemiol Rec. 2007; 82:93–104.

2. Anonymous . Pneumococcal vaccines WHO position paper--2012. Wkly Epidemiol Rec. 2012; 87:129–144.

3. Anonymous . 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec. 2008; 83:373–384.

4. Janoff EN, Musher DM. Streptococcus pneumoniae. In : Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, PA: Elsevier;2015. p. 2310–2327.

5. Backhaus E, Berg S, Andersson R, Ockborn G, Malmström P, Dahl M, Nasic S, Trollfors B. Epidemiology of invasive pneumococcal infections: manifestations, incidence, and case fatality rate correlated to age, gender, and risk factors. BMC Infect Dis. 2016; 16:367.

6. Navarro-Torné A, Dias JG, Hruba F, Lopalco PL, Pastore-Celentano L, Gauci AJ; Invasive Pneumococcal Disease Study Group. Risk factors for death from invasive pneumococcal disease, Europe, 2010. Emerg Infect Dis. 2015; 21:417–425.

7. Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Mason EO Jr. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013; 32:203–207.

8. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003; 348:1737–1746.

9. Papadatou I, Spoulou V. Pneumococcal vaccination in high-risk individuals: are we doing it right? Clin Vaccine Immunol. 2016; 23:388–395.

10. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis. 1992; 165:Suppl 1. S49–S52.

11. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T; Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014; 63:822–825.

12. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep. 2005; 54:893–897.

13. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis. 2009; 49:205–212.

14. von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C, Madhi SA, Zell ER, Verani JR, O’Brien KL, Whitney CG, Klugman KP, Cohen C. GERMS-SA Investigators. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med. 2014; 371:1889–1899.

15. Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, Konradsen HB, Nahm MH. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev. 2015; 28:871–899.

16. Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof. Accessed 13 December 2016. Available at: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=20150202309&OS=20150202309&RS=20150202309.

17. World Health Organization (WHO). Immunization, vaccines, and biologicals: Data, statistics and graphics. Accessed 7 December 2016. Available at: http://www.who.int/immunization/monitoring_surveillance/data/en.

18. World Health Organization (WHO). Vaccine in national immunization programme update. Accessed 22 November 2016. Available at: http://www.who.int/immunization/monitoring_surveillance/VaccineIntroStatus.pptx.

19. Cho EY, Kang HM, Lee J, Kang JH, Choi EH, Lee HJ. Changes in serotype distribution and antibiotic resistance of nasopharyngeal isolates of Streptococcus pneumoniae from children in Korea, after optional use of the 7-valent conjugate vaccine. J Korean Med Sci. 2012; 27:716–722.

20. Korea Centers for Disease Control and Prevention (KCDC). 2013 Korea National Immunization Survey. Accessed 12 December 2016. Available at: http://cdc.go.kr/CDC/contents/CdcKrContentView.jsp?cid=71894&menuIds=HOME001-MNU1132-MNU2430-MNU2559-MNU2560.

21. Choi WS, Choi JH, Kwon KT, Seo K, Kim MA, Lee SO, Hong YJ, Lee JS, Song JY, Bang JH, Choi HJ, Choi YH, Lee DG, Cheong HJ; Committee of Adult Immunization. Korean Society of Infectious Diseases. Revised adult immunization guideline recommended by the Korean society of infectious diseases, 2014. Infect Chemother. 2015; 47:68–79.

22. Gray BM, Converse GM 3rd, Dillon HC Jr. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis. 1980; 142:923–933.

23. Faden H, Duffy L, Wasielewski R, Wolf J, Krystofik D, Tung Y. Relationship between nasopharyngeal colonization and the development of otitis media in children. Tonawanda/Williamsville Pediatrics. J Infect Dis. 1997; 175:1440–1445.

24. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O’Brien KL; Pneumococcal Carriage Group. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012; 11:841–855.

25. Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci. 2013; 28:4–15.

26. Avery OT, Dubos R. The protective action of a specific enzyme against type III pneumococcus infection in mice. J Exp Med. 1931; 54:73–89.

27. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005; 5:83–93.

28. Briles DE, Crain MJ, Gray BM, Forman C, Yother J. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun. 1992; 60:111–116.

29. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004; 4:144–154.

30. Bogaert D, Engelen MN, Timmers-Reker AJ, Elzenaar KP, Peerbooms PG, Coutinho RA, de Groot R, Hermans PW. Pneumococcal carriage in children in The Netherlands: a molecular epidemiological study. J Clin Microbiol. 2001; 39:3316–3320.

31. Givon-Lavi N, Fraser D, Porat N, Dagan R. Spread of Streptococcus pneumoniae and antibiotic-resistant S. pneumoniae from day-care center attendees to their younger siblings. J Infect Dis. 2002; 186:1608–1614.

32. Kim SM, Lee KY, Shin YK, Park SE, Ma SH, Min AY, Kang JH. Epidemiological study of pneumococcal nasal carriage and serotypes among Korean children. Korean J Pediatr. 2004; 47:611–616.

33. Dowell SF, Whitney CG, Wright C, Rose CE Jr, Schuchat A. Seasonal patterns of invasive pneumococcal disease. Emerg Infect Dis. 2003; 9:573–579.

34. Walter ND, Taylor TH Jr, Dowell SF, Mathis S, Moore MR; Active Bacterial Core Surveillance System Team. Holiday spikes in pneumococcal disease among older adults. N Engl J Med. 2009; 361:2584–2585.

35. Rodrigo C, Bewick T, Sheppard C, Greenwood S, Macgregor V, Trotter C, Slack M, George R, Lim WS. Pneumococcal serotypes in adult non-invasive and invasive pneumonia in relation to child contact and child vaccination status. Thorax. 2014; 69:168–173.

36. Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J, Yagupsky P, Fraser D. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis. 2002; 185:927–936.

37. Millar EV, Watt JP, Bronsdon MA, Dallas J, Reid R, Santosham M, O’Brien KL. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis. 2008; 47:989–996.

38. Roca A, Hill PC, Townend J, Egere U, Antonio M, Bojang A, Akisanya A, Litchfield T, Nsekpong DE, Oluwalana C, Howie SR, Greenwood B, Adegbola RA. Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. PLoS Med. 2011; 8:e1001107.

39. Nzenze SA, Shiri T, Nunes MC, Klugman KP, Kahn K, Twine R, de Gouveia L, von Gottberg A, Madhi SA. Temporal changes in pneumococcal colonization in a rural African community with high HIV prevalence following routine infant pneumococcal immunization. Pediatr Infect Dis J. 2013; 32:1270–1278.

40. Hammitt LL, Akech DO, Morpeth SC, Karani A, Kihuha N, Nyongesa S, Bwanaali T, Mumbo E, Kamau T, Sharif SK, Scott JA. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health. 2014; 2:e397–405.

41. Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012; 31:297–301.

42. Loughlin AM, Hsu K, Silverio AL, Marchant CD, Pelton SI. Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts’ children. Pediatr Infect Dis J. 2014; 33:504–510.

43. Davis SM, Deloria-Knoll M, Kassa HT, O’Brien KL. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine. 2013; 32:133–145.

44. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O’Brien KL, Moore MR; Serotype Replacement Study Group. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013; 10:e1001517.

45. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010; 201:32–41.

46. Myint TT, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, Sprenger R, Bonnet E. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther. 2013; 30:127–151.

47. Cabaj JL, Nettel-Aguirre A, MacDonald J, Vanderkooi OG, Kellner JD. Influence of childhood pneumococcal conjugate vaccines on invasive pneumococcal disease in adults with underlying comorbidities in Calgary, Alberta (2000-2013). Clin Infect Dis. 2016; 62:1521–1526.

48. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014; 59:1066–1073.

49. Kendall BA, Dascomb KK, Mehta RR, Stockmann C, Mason EO, Ampofo K, Pavia AT, Byington CL. Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children. Vaccine. 2016; 34:474–478.

50. Moore CE, Paul J, Foster D, Mahar SA, Griffiths D, Knox K, Peto TE, Walker AS, Crook DW; Oxford Invasive Pneumococcal Surveillance Group. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. J Infect Dis. 2014; 210:1001–1011.

51. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, Miller L, Scherzinger K, Thomas A, Farley MM, Zell ER, Taylor TH Jr, Pondo T, Rodgers L, McGee L, Beall B, Jorgensen JH, Whitney CG. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015; 15:301–309.

52. Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015; 15:535–543.

53. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011; 11:760–768.

54. Regev-Yochay G, Paran Y, Bishara J, Oren I, Chowers M, Tziba Y, Istomin V, Weinberger M, Miron D, Temper V, Rahav G, Dagan R; IAIPD group. Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study. Vaccine. 2015; 33:1135–1142.

55. Greenberg D, Lee JT. Editorial commentary: pneumococcal vaccination in adults: Do we have to recalculate our approach? Clin Infect Dis. 2016; 62:1527–1528.

56. Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, Slack M, Ladhani SN, Miller E, Goldblatt D. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014; 14:839–846.

57. Horácio AN, Silva-Costa C, Lopes JP, Ramirez M, Melo-Cristino J; Portuguese Group for the Study of Streptococcal Infections. Serotype 3 remains the leading cause of invasive pneumococcal disease in adults in Portugal (2012–2014) despite continued reductions in other 13-valent conjugate vaccine serotypes. Front Microbiol. 2016; 7:1616.

58. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O’Brien KL. AGEDD Adult Pneumococcal Burden Study Team, Andreo F, Beovic B, Blanco S, Boersma WG, Boulware DR, Butler JC, Carratalà J, Chang FY, Charles PG, Diaz AA, Domínguez J, Ehara N, Endeman H, Falcó V, Falguera M, Fukushima K, Garcia-Vidal C, Genne D, Guchev IA, Gutierrez F, Hernes SS, Hoepelman AI, Hohenthal U, Johansson N, Kolek V, Kozlov RS, Lauderdale TL, Mareković I, Masiá M, Matta MA, Miró Ò, Murdoch DR, Nuermberger E, Paolini R, Perelló R, Snijders D, Plečko V, Sordé R, Strålin K, van der Eerden MM, Vila-Corcoles A, Watt JP. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013; 8:e60273.

59. Pletz MW, Ewig S, Rohde G, Schuette H, Rupp J, Welte T, Suttorp N, Forstner C; CAPNETZ Study Group. Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay. Vaccine. 2016; 34:2342–2348.

60. Rodrigo C, Bewick T, Sheppard C, Greenwood S, McKeever TM, Trotter CL, Slack M, George R, Lim WS. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J. 2015; 45:1632–1641.

61. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015; 372:1114–1125.

62. van Werkhoven CH, Hollingsworth RC, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Sanders EA, Bonten MJ. Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly. Vaccine. 2016; 34:3275–3282.

63. Kim SH, Song JH, Chung DR, Thamlikitkul V, Yang Y, Wang H, Lu M, So TM, Hsueh PR, Yasin RM, Carlos CC, Pham HV, Lalitha MK, Shimono N, Perera J, Shibl AM, Baek JY, Kang CI, Ko KS, Peck KR; ANSORP Study Group. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother. 2012; 56:1418–1426.

64. Kraicer-Melamed H, O’Donnell S, Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis. Vaccine. 2016; 34:1540–1550.